Crossmark

Risk of recurrent venous thromboembolism and major bleeding according to risk factor profiles in Asian patients: a subgroup analysis EINSTEIN-Extension and EINSTEIN-CHOICE

Crossref DOI link: https://doi.org/10.1186/s12959-024-00609-4

Published Online: 2024-06-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamada, Norikazu

Fu, Weiguo

Shi, Zhenyu

Park, Ki-Hyuk

Kim, Hyo-Soo

Dai, Xiangchen

Lensing, Anthonie WA

Pap, Akos F

Kohno, Tomoko

Tajima, Tsubasa

Watakabe, Tadashi

Mitsumori, Tomoyuki
Funding

Funding for this research was provided by:

Bayer AG (NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439, NCT00439725 and NCT02064439)
License Information

Text and Data Mining valid from 2024-06-06

Version of Record valid from 2024-06-06
More Information

Article History

Received: 31 January 2024

Accepted: 16 April 2024

First Online: 6 June 2024

Declarations

:

: Both protocols (NCT00439725 and NCT02064439) were approved by the institutional review board at each participating center and written informed consent was obtained from all patients.

: AWAL, AFP, TK, TT, TW and TM are employees of Bayer.

Document is current

Any future updates will be listed below